BioSkryb Announces Commercial Launch of ResolveOME System and BaseJumper Bioinformatics Platform
Comprehensive system that enables unmatched single cell multiomic analysis is now widely available following the completion of a successful Early Access Program
DURHAM, N.C. – February 7, 2023 - BioSkryb Genomics, a pioneer in comprehensive single cell multiomic research solutions, today announced t…
January 31, 2023
BioSkryb Welcomes Accomplished Genomics Executive Suresh Pisharody as New CEO
Suresh Pisharody brings strong leadership experience honed at Illumina, Thermo Fisher Scientific, and Guardant Health to lead BioSkryb in its next phase of growth
DURHAM, N.C. – January 31, 2023 - BioSkryb Genomics, a pioneer in comprehensive single-cell multi-omic research solutions, has appointed …
October 18, 2022
BioSkryb Genomics and Cooper Surgical Ink Multi-Year Deal to Accelerate Clinical Discovery and Diagnostics in Women’s Reproductive Health
New partnership brings transformative, high-resolution single-cell genomic technology to the field of preimplantation genetic testing in the pursuit of improved discovery and clinical outcomes.
DURHAM, N.C., October 18, 2022 – BioSkryb Genomics, a pioneer in developing scientifically advanced single…
September 21, 2022
BioXpedia A/S and BioSkryb Genomics Announce European Partnership to Provide Groundbreaking, Single-Cell, Multiomic Analysis for Novel Target Identification and Therapeutic Development
This new partnership brings high-resolution, single-cell whole genome and whole transcriptome analysis to Europe. This partnership will enable novel insights and deep cellular characterization required in the evaluation, creation, and validation of new generation biologics and therapeutics in target…
May 31, 2022
BioSkryb Genomics Launches ResolveOME Early Access Program for Full Genome and Transcriptome Amplification from a Single Cell, in Conjunction with Its Innovative Bioinformatics Platform, BaseJumper™
DURHAM, N.C., May 31, 2022--(BUSINESS WIRE)--BioSkryb Genomics, a biotech company developing advanced single-cell analysis tools, today announced the launch of the Early Access Program (EAP) for ResolveOME, a unified, single-cell workflow that amplifies the complete genome and full-length mRNA …
February 9, 2022
BioSkryb Genomics and ALS Automated Lab Solutions GmbH Sign U.S. Distribution Agreement to Power Unprecedented Single Cell Spatial Genomics
DURHAM, N.C.--(BUSINESS WIRE)--BioSkryb Genomics, a leader of single-cell genome amplification, and ALS Automated Lab Solutions GmbH, developers of a multi-patented spatial single cell and colony picking technology platform, today announced a U.S. distribution agreement to power comprehensive s…
October 12, 2021
BioSkryb Completes Move into New Global Headquarters in Durham, N.C.
Move supports company’s multi-year strategic growth initiative; advances retention, attraction, and expansion of the team; enhances the ability to serve customers; and demonstrates Company's commitment to the region
Meet BioSkryb’s New Commercial Team Members Providing Customer Care and Technical Support
We are excited to welcome three new team members who bring deep scientific knowledge as well as technical experience in supporting researcher needs in applying new genomic and molecular biology solutions.
“Just as we know each cell is unique, so are our people,” said Jay West, Ph.D., CEO and cofoun…
August 4, 2021
In-depth empowerment and innovation! 2021 MGI & IDG Capital Life and Health Acceleration Camp officially opens
JULY 31 - HUATAI ZHI MADE (MGI), IDG INVESTMENT INNOVATION INSTITUTE AND BLUE RAINBOW LIFE SCIENCES ACCELERATOR JOINTLY ORGANIZED BY THE MGI & IDG CAPITAL ACCELERATED LIFE AND HEALTH BUSINESS (HEREINAFTER REFERRED TO AS "ACCELERATED CAMP") IN THE NANSHAN DISTRICT, SHENZHEN, IDG CAPITAL INNOVATION TH…
June 30, 2021
BioSkryb Appoints Gary Harton, Ph.D., Chief Scientific Officer
Dr. Harton to lead the translation of BioSkryb’s Primary Template-directed Amplification (PTA) technology into breakthrough diagnostic applications for targeted indications, including cancer and neurological disorders
DURHAM, N.C., June 30, 2021 -- BioSkryb, Inc., today announced the expansion of th…